Skip to main content

01.04.2015 | Gynecologic Cancers (NS Reed, Section Editor) | Ausgabe 4/2015

Current Oncology Reports 4/2015

Radical Surgery in Ovarian Cancer

Current Oncology Reports > Ausgabe 4/2015
Deepa Maheswari Narasimhulu, Fady Khoury-Collado, Dennis S. Chi
Wichtige Hinweise
This article is part of the Topical Collection on Gynecologic Cancers.


While there is an ongoing debate regarding the timing of the maximal surgical effort in epithelial ovarian cancer, it is well established that patients with suboptimal tumor debulking derive no benefit from the surgical procedure. The amount of residual disease after cytoreductive surgery has been repeatedly identified as a strong predictor of survival, and accordingly, the surgical effort to achieve the goal of complete gross tumor resection has been constantly evolving. Centers that have adopted the concept of radical surgery in patients with advanced ovarian cancer have reported improvements in their patients’ survival. In addition to the expected improvements in the pharmacologic treatment of this disease, some of the next challenges in the surgical management of ovarian cancer include the preoperative prediction of suboptimal debulking, improving the drug delivery to the tumor, and increasing access to centers of excellence in ovarian cancer regardless of geographical, financial, or other social barriers. This review will discuss an update on the role of surgery in the treatment of primary epithelial ovarian cancer as it has evolved since the emergence of the concept of surgical cytoreduction.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2015

Current Oncology Reports 4/2015 Zur Ausgabe

Gastrointestinal Cancers (BG Czito, Section Editor)

Contemporary Surgical Options for Metastatic Colorectal Cancer

Gynecologic Cancers (NS Reed, Section Editor)

Adenocarcinoma of the Cervix: Should We Treat It Differently?

Evolving Therapies (R Bukowski, Section Editor)

Activin Receptor Inhibitors—Dalantercept

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.


Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.